Cyfuse Biomedical K.K. (TYO:4892)
Japan · Delayed Price · Currency is JPY 570.00
0.00 (0.00%)
Aug 27, 2026, 3:30 PM JST
Cyfuse Biomedical K.K. Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 305 | 230 | 54 | 61 | 374 | 708 | |
Revenue Growth | 369.23% | 325.93% | -11.47% | -83.69% | -47.17% | 416.79% |
Cost of Revenue | 141 | 117 | 38 | 23 | 133 | 137 |
Gross Profit | 164 | 113 | 16 | 38 | 241 | 571 |
Selling, General & Admin | 509 | 512 | 428 | 351 | 346 | 500 |
Research & Development | 416 | 416 | 469 | 375 | 303 | - |
Operating Expenses | 939 | 942 | 912 | 735 | 666 | 500 |
Operating Income | -775 | -829 | -896 | -697 | -425 | 71 |
Interest Expense | -21 | -15 | -10 | -10 | -7 | -5 |
Interest & Investment Income | 5 | 3 | - | - | - | - |
Currency Exchange Gain (Loss) | - | - | - | - | -1 | - |
Other Non Operating Income (Expenses) | -2 | 80 | 36 | 121 | - | 78 |
EBT Excluding Unusual Items | -793 | -761 | -870 | -586 | -433 | 144 |
Other Unusual Items | - | - | - | - | -38 | - |
Pretax Income | -793 | -761 | -870 | -586 | -471 | 144 |
Income Tax Expense | 2 | 2 | 2 | 3 | 2 | 2 |
Net Income to Company | - | -763 | -872 | -589 | -473 | 142 |
Net Income | -795 | -763 | -872 | -589 | -473 | 142 |
Net Income to Common | -795 | -763 | -872 | -589 | -473 | 142 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 10 | 9 | 8 | 8 | 3 | 1 |
Shares Outstanding (Diluted) | 10 | 9 | 8 | 8 | 3 | 1 |
Shares Change | 18.27% | 9.33% | 3.05% | 192.85% | 432.99% | - |
EPS (Basic) | -82.10 | -86.69 | -108.31 | -75.39 | -177.31 | 283.72 |
EPS (Diluted) | -82.10 | -86.69 | -108.31 | -75.39 | -177.31 | 283.72 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -696 | -581 | -768 | -581 | -631 | - |
Free Cash Flow Per Share | -71.88 | -66.01 | -95.40 | -74.37 | -236.54 | - |
Gross Margin | 53.77% | 49.13% | 29.63% | 62.30% | 64.44% | 80.65% |
Operating Margin | -254.10% | -360.44% | -1659.26% | -1142.62% | -113.64% | 10.03% |
Profit Margin | -260.66% | -331.74% | -1614.82% | -965.57% | -126.47% | 20.06% |
Free Cash Flow Margin | -228.20% | -252.61% | -1422.22% | -952.46% | -168.72% | - |
EBITDA | -742 | -792 | -858 | -657 | -362 | - |
EBITDA Margin | -243.28% | - | - | - | -96.79% | - |
D&A For EBITDA | 33 | 37 | 38 | 40 | 63 | - |
EBIT | -775 | -829 | -896 | -697 | -425 | 71 |
EBIT Margin | -254.10% | - | - | - | -113.64% | 10.03% |
Effective Tax Rate | - | - | - | - | - | 1.39% |